Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Scripps Health

ClinicalTrials.gov Identifier:

NCT01729559

First received: November 14, 2012

Last updated: June 7, 2016

Last verified: June 2016

History of Changes

Results First Received: July 29, 2015

Study Type:	Interventional
Study Design:	Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Single Blind (Outcomes Assessor); Primary Purpose: Prevention
Conditions:	Venous Thromboembolic Disease Deep Vein Thrombosis Pulmonary Embolism
Interventions:	Drug: 5000 Units unfractionated Heparin Q 8 hr Drug: 30mg enoxaparin Q12 hr

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
From November 15, 2012 through September 15, 2014, consecutively admitted adult trauma patients were evaluated for eligibility for the study. Patients aged 18 years and older and at risk for Venous thromboembolic event (VTE) based on the American College of Chest Physicians guidelines were included.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Those with an estimated Injury Severity Score (ISS) equal to or less than 9, those expected to have a hospital length of stay less than seven days by reason of discharge or death, and prisoners were excluded.

Reporting Groups

	Description
5000 Units Unfractionated Heparin Q 8 Hours	Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service. 5000 Units unfractionated Heparin Q 8 hours: Venous thromboembolic prophylaxis medication. Patients were randomly assigned.
30mg Enoxaparin Q12 Hours	Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service. 30mg enoxaparin Q12 hours: Venous thromboembolic prophylaxis

Description

5000 Units Unfractionated Heparin Q 8 Hours

Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.

5000 Units unfractionated Heparin Q 8 hours: Venous thromboembolic prophylaxis medication. Patients were randomly assigned.

30mg Enoxaparin Q12 Hours

Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.

30mg enoxaparin Q12 hours: Venous thromboembolic prophylaxis

Participant Flow: Overall Study

	5000 Units Unfractionated Heparin Q 8 Hours	30mg Enoxaparin Q12 Hours
STARTED	251	244
COMPLETED	220	216
NOT COMPLETED	31	28
Protocol Violation	31	28

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Basic demographic and clinical characteristics of trauma patients who met all inclusion criteria.

Reporting Groups

	Description
5000 Units Unfractionated Heparin Q 8 Hours	Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service. 5000 Units unfractionated Heparin Q 8 hours: Venous thromboembolic prophylaxis medication. Patients were randomly assigned.
30mg Enoxaparin Q12 Hours	Randomly assigned trauma patients to receive Low Molecular Weight Heparin (30mg enoxaparin) given subcutaneously every twelve hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service. 30mg enoxaparin Q12 hours: Venous thromboembolic prophylaxis
Total	Total of all reporting groups

Description

5000 Units Unfractionated Heparin Q 8 Hours

Low Dose Unfractionated Heparin (5000 Units) given every eight hours until primary or secondary outcome measure reached, discharge, or >30 days on trauma service.

5000 Units unfractionated Heparin Q 8 hours: Venous thromboembolic prophylaxis medication. Patients were randomly assigned.

30mg Enoxaparin Q12 Hours

30mg enoxaparin Q12 hours: Venous thromboembolic prophylaxis

Total

Total of all reporting groups

Baseline Measures

5000 Units Unfractionated Heparin Q 8 Hours

30mg Enoxaparin Q12 Hours

Total

Overall Participants Analyzed
[Units: Participants]

220

216

436

Age
[Units: Years]
Mean (Standard Deviation)

46.5 (21.2)

46.4 (20.8)

46.4 (21.0)

Gender
[Units: Participants]

Female

124

Male

160

152

312

Region of Enrollment
[Units: Participants]

United States

220

216

436

Body Mass Index
[Units: Kg/m^2]
Mean (Standard Deviation)

26.1 (4.5)

26.9 (5.2)

26.5 (4.9)

Injury Severity Score ^[1]
[Units: Units on a scale]
Median (Full Range)

10
(1 to 50)

9
(1 to 38)

9
(1 to 50)

^[1]

The Injury Severity Score (ISS) is an anatomical scoring system that provides an overall score for patients with multiple injuries. Each injury is assigned an Abbreviated Injury Scale (AIS) score allocated to one of six body regions (Head, Face, Chest, Abdomen, Extremities, External). The highest AIS scores among the three most severely injured body regions are squared and added together to produce the total ISS score. The ISS score ranges from 0 to 75. Each AIS score ranges from 1 to 6 (6 denotes an unsurvivable injury).

Outcome Measures

Show All Outcome Measures

1. Primary:

Lower Extremity Deep Vein Thrombosis [ Time Frame: Within 30 days of hospital admission ]

Show Outcome Measure 1

2. Primary:

Pulmonary Embolus [ Time Frame: Within 30 days from admission to hospital ]

Show Outcome Measure 2

3. Secondary:

Bleeding Event [ Time Frame: Within 30 days of admission to hospital ]

Show Outcome Measure 3

4. Secondary:

Heparin Induced Thrombocytopenia [ Time Frame: Within 30 of admission to hospital ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
The lack of long-term follow-up to identify VTE events among patients who were either transferred or readmitted to other facilities with VTE-related events was not performed. Published risk estimates were inaccurate for our sample size calculation.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Steven R. Shackford, MD
Organization: Scripps Mercy Hospital
phone: 619-299-2600
e-mail: shackford.steven@scrippshealth.org

Responsible Party:	Scripps Health
ClinicalTrials.gov Identifier:	NCT01729559 History of Changes
Other Study ID Numbers:	IRB-12-5973
Study First Received:	November 14, 2012
Results First Received:	July 29, 2015
Last Updated:	June 7, 2016

To Top